Core Insights - TELA Bio, Inc. achieved a 16% full-year revenue growth and record fourth-quarter results despite a significant rebuild of its commercial organization [5] - The company attributes its performance to strong adoption in Europe and continued momentum in its IHR, LPR, and LiquiFix product lines [5] - A strategic shift to a 'deep and narrow' geographic strategy has been implemented, focusing on high-volume institutions to cultivate multiple users per site [5] Financial Performance - The hernia business mix transitioned from 70% ventral to 50%, with notable growth in inguinal and hiatal procedures driven by robotic surgery adoption [5] - The company maintained operating discipline and improved leverage, using savings to fund increased customer education and training events [5] - TELA Bio anticipates at least 8% revenue growth for the full year 2026, adopting a cautious approach due to the restructuring of the sales force [5][7] Strategic Priorities - A full market launch of a long-term resorbable OviTex product is planned for April 1, 2026, to compete with biosynthetic alternatives [5] - The focus for 2026 will be on 'contract execution,' translating existing agreements into active clinical usage and revenue [5] - Plans to expand European presence into Continental markets and introduce the PRS portfolio outside the U.S. by late 2026 or early 2027 [5] Operational Changes - The U.S. commercial leadership has been restructured to implement a General Manager structure, bringing decision-making closer to local customers [5] - Identified Q1 headwinds include severe January weather affecting elective procedures and temporary disruptions from splitting sales territories [5] - While unit growth remains high at 22% in hernia, average selling prices (ASPs) are impacted by a shift towards smaller units used in robotic and laparoscopic procedures [5] Financial Flexibility - The company upsized its debt facility and raised equity capital in late 2025 to ensure financial flexibility during the commercial transition [5]